Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Forecasted Growth Rate and Market Size of the Anthracycline Market?

The market size of anthracycline has demonstrated robust growth in the past few years. There is a prediction of its increase from $1.52 billion in 2024 to $1.6 billion in 2025, indicating a compound annual growth rate (CAGR) of 5.2%. Factors contributing to the growth during the historic period include the escalating occurrence of cancer, the surge in demand for tailored cancer treatment, growing knowledge of anthracyclines advantages, and investment in anthracycline.

In the coming years, a significant rise is projected in the size of the anthracycline market. The anticipated growth will reach “$2.08 billion by 2029, with a compound annual growth rate (CAGR) of 6.8%.” Factors contributing to this growth in the forecast period include increasing cognizance about cancer treatments, investments made towards R&D for cancer therapies, a growing demand for potent and convenient cancer treatments, rising number of cancer screening programs, and government initiatives. Within the forecast period, prominent trends will involve advancements in anthracycline formulations, combination therapies, cardioprotective strategies, and development of biosimilars of anthracyclines.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12914&type=smp

Which Factor Is Shaping The Future Of The Anthracycline Market?

The anthracycline market is predicted to surge owing to the rising prevalence of cancer. Cancer is a range of diseases which occur when abnormal cells in the body multiply uncontrollably, breach their normal boundaries and either metastasize to other organs or infiltrate neighboring tissues. Anthracyclines, a type of chemotherapy drugs, significantly contribute to cancer treatment as they obstruct cell division by tampering with DNA structure and inhibiting its function. The American Cancer Society Inc., a non-profit health organization in the US, predicts 1.9 million new cancer incidences in 2023, up from 1.8 million in 2020. Moreover, about 609,820 cancer-related fatalities are projected in 2023, a slight surge from an estimated 606,520 in 2020. Hence, the escalating prevalence of cancer is fueling the expansion of the anthracycline market.

The anthracycline market covered in this report is segmented –

1) By Drugs: Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mitoxantrone, Valrubicin

2) By Dosage: Powder, Capsule, Solution, Injection, Suspension, Other Dosages

3) By Application: Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Hodgkin’s Lymphoma, Non-Hodgkin’s Lymphoma, Bladder Cancer, Breast Cancer, Other Metastatic Cancers

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Daunorubicin: Daunorubicin Hydrochloride, Liposomal Daunorubicin

2) By Doxorubicin: Doxorubicin Hydrochloride, Liposomal Doxorubicin

3) By Epirubicin: Epirubicin Hydrochloride

4) By Idarubicin: Idarubicin Hydrochloride

5) By Mitoxantrone: Mitoxantrone Hydrochloride

6) By Valrubicin: Valrubicin Hydrochloride

What Are The Leading Trends And Opportunities In The Anthracycline Sector?

Key players in the anthracycline market are prioritizing the creation of ground-breaking products like non-cardiotoxic formulations in an effort to enhance the security aspect of chemotherapy solutions. Non-cardiotoxic formulations are essentially treatments produced to curtail or abolish harm caused to the heart, specifically the detrimental effects often linked to some chemotherapy medicines including anthracyclines that could result in heart failure or other heart-related complications. For instance, Orphan Drug Designation for Annamycin, a progressive anthracycline, was introduced for the treatment of acute myeloid leukemia (AML) in April 2024 by the European Medicines Agency based in the Netherlands. This product offers hefty incentives for the creation of treatments for rare ailments, encompassing seven years of market exclusivity after approval thereby preventing other manufacturers from commercially distributing the same medicine for the same purpose. Furthermore, businesses stand to gain from tax rebates which cover up to half the cost of clinical trials, exemption from application costs, and regulatory support from the FDA. These benefits are all aimed at alleviating the monetary strain linked with the development of drugs for smaller patient groups.

Which Companies Hold The Largest Market Share In The Anthracycline Sector?

Major companies operating in the anthracycline market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Bristol-Myers Squibb Company, Fresenius SE & Co. KGaA, Merck & Co. Inc., Gilead Sciences Inc., Zydus Lifesciences Limited, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Jazz Pharmaceuticals Inc., Gland Pharma Limited, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Endo Pharmaceuticals Inc., Amneal Pharmaceuticals Inc., Zhejiang Hisun Pharmaceutical Co. Ltd., Accord Healthcare Limited, Athenex Inc., Miracalus Pharma Pvt. Ltd., Transo-Pharm Usa LLC, BluePoint Laboratories, Areva Pharmaceuticals Inc., GeneraMedix Inc., Salius Pharma Pvt. Ltd.

https://www.thebusinessresearchcompany.com/report/anthracycline-global-market-report

How Does Regional Performance Compare Across The Anthracycline Industry?

Asia-Pacific was the largest region in the anthracycline market in 2024. The regions covered in anthracycline market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12914&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model